A Randomized Phase 3 Study Evaluating Cystectomy with Perioperative Pembrolizumab and Cystectomy with Perioperative Enfortumab Vedotin and Pembrolizumab versus Cystectomy Alone in Cisplatin-Ineligible Participants with Muscle-Invasive Bladder Cancer (KEYNOTE-905/EV-303)
Cisplatin-ineligible participants with muscle-invasive bladder cancer
Pulau Pinang Hospital
PRINCIPAL INVESTIGATOR
SOO HOO HWOEI FEN
CONTACT
General line: ’04-2225 333
CRC: 042225 767 / 2225 762 / 2225 766 / 2225 586
Dr. Yoon Chee Kin, Ketua Jabatan
dryoonck@moh.gov.my (email)
Sister Zarina Bt Che Umar, Admin Manager
zarinacu@gmail.com (Email)
Sarawak General Hospital
PRINCIPAL INVESTIGATOR
Hadi ab Jalil
CONTACT
General line: 082 – 276666
CRC: 082-276820 (Tel)
082-276823 (Fax)
Tiong Lee Len, Admin Manager
leelen.crc@gmail.com (Email)
Facebook
A phase 3, randomized, double-blind, placebo-controlled clinical trial to study the efficacy and safety of pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) versus CRT alone in participants with muscle-invasive bladder cancer (MIBC) (KEYNOTE-992)
Muscle-invasive bladder cancer
Pulau Pinang Hospital
PRINCIPAL INVESTIGATOR
SOO HOO HWOEI FEN
CONTACT
SC: Nur Awatif Akmal, Nurul Ainaa Jasmin
CRC: 042225767 / 762